Global Antiretroviral Therapy Market 2017-2021

Global antiretroviral therapy market forecast

The pre-exposure prophylaxis (PrEP) is the precautionary tablet that is used daily to prevent the human immunodeficiency virus (HIV) onset. Technavio’s market research report identifies that the presence of PrEP will be one of the primary drivers for the global antiretroviral therapy market growth till 2021. Several individuals who are at high risk of acquiring HIV infections are highly benefited from these medications. As per the centers for disease control and prevention (CDC), the risks associated with HIV is reduced by 90% due to the administration of PrEP agents. In addition, PrEP agents reduce the HIV risk in drug users by over 70%. Consequently, the increasing administration rate of antiretroviral agents such as PrEP drugs to HIV negative people will result in a reduced risk of infection, which in turn, will boost the popularity of the antiretroviral therapy. The administration of TRUVADA for PrEP from Gilead is high in the US due to the availability of reimbursement programs. According to the antiretroviral therapy market overview, Technavio’s market research analysts predict that this global market will register a revenue of close to USD 28 billion by 2021.

One of the key trends that will gain traction in the global antiretroviral therapy market during the estimated period is the rising focus on the advanced formulations. Maximum efficacy can be attained through combination products by focusing more on the research and development of antiretroviral molecules. For instance, ODEFSEY serves as a complete regimen for the treatment of HIV-1 infection. This is a combination of emtricitabine, rilpivirine, and tenofovir alafenamide.

Competitive landscape and key vendors

The antiretroviral therapy market is consolidated and characterized by the presence of prominent players. The existing vendors are increasingly focusing on the development of novel drugs by investing heavily in research and developmental activities. Furthermore, they are also focusing on product innovations and advancements due to the rising need for better safety profile and convenient dosing frequency of drugs.

Key vendors in this market are -

• Gilead
• ViiV Healthcare
• Janssen Pharmaceuticals
• F. Hoffmann-La Roche

Other prominent vendors in the market include Abbvie, Boehringer Ingelheim, Bionor Pharma, Vertex Pharmaceuticals, and Mylan

Segmentation by drug class and analysis of the antiretroviral therapy market

• Multiclass combination products
• NRTI
• Integrase inhibitors
• NNRTIs

The demand for multiclass combination products is high due to the better clinical outcomes and activity against resistant strains. The combination tablet is replacing the conventional treatment methods (requires multiple tablets) due to the increased patience compliance to only one tablet. TRIUMEQ and ATRIPLA are the two most popular drugs of this class. The high sales volume of these antiretroviral drugs will drive the antiretroviral therapy market’s growth in the multiclass combination products segment.

Segmentation by geography and analysis of the antiretroviral therapy market

• Americas
• APAC
• EMEA

The healthcare spending for HIV care and treatment is increasing. In addition, the US is focusing on enhancing the ability to identify the HIV-infected patients by launching the HIV care continuum initiative. This in turn, will boost the involvement of community-based organizations that are non-traditional providers of HIV care. Furthermore, the enrolment of patients suffering from HIV infection to the comprehensive health insurance program is increasing due to the establishment of the affordable care act in 2010 in the US. This in turn, will result in an increased number of infected individuals opting for ART.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global antiretroviral therapy market?
• What are the key market trends impacting the growth of the global antiretroviral therapy market?
• What are the challenges to market growth?
• Who are the key vendors in the global antiretroviral therapy market?
• What are the market opportunities and threats faced by the vendors in the global antiretroviral therapy market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global antiretroviral therapy market?

Technavio also offers customization on reports based on specific client requirement.